Mutant p27Kip1 and its Potential Effect as Hepatocellular Gene Therapy

Archives of Medical Research

Volumn 39, Issue 6, 2008, Pages 573-581

  Lu, Mudan ^a   Fei, Min ^b   Cheng, Chun ^a   Wang, You ^a   He, Song ^a   Zhao, Yueming ^a   Gao, Shangfeng ^a   Ke, Qing ^a   Li, Peng ^a   Cui, Xiaopeng ^a   Shen, Aiguo ^a  

^a NANTONG UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

Cell cycle; p p27 Thr157; p27Kip1; Proliferation; SMMC7721; Transfection

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; RETINOBLASTOMA PROTEIN;

ARTICLE; CELL COUNT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL FRACTIONATION; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DRUG EFFECT; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE LOCATION; GENE THERAPY; GENE TRANSLOCATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MUTANT; PROTEIN EXPRESSION; WESTERN BLOTTING; WILD TYPE;

BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA PRIMERS; FLUORESCENT ANTIBODY TECHNIQUE; GENE THERAPY; HUMANS; LIVER NEOPLASMS; MUTAGENESIS, SITE-DIRECTED; MUTATION; SUBCELLULAR FRACTIONS;

EID: 47749132287     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2008.05.002     Document Type: Article

References (57)

1. McGlynn K.A., Tsao L., Hsing A.W., Devesa S.S., and Fraumeni Jr. J.F. International trends and patterns of primary liver cancer. Int J Cancer 94 (2001) 290-296
2. Sherr C.J. Cancer cell cycles. Science 274 (1996) 1672-1677
3. Sherr C.J., and Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9 (1995) 1149-1163
4. Morgan D.O. Principles of CDK regulation. Nature 374 (1995) 131-134
5. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., and Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366 (1993) 701-704
6. Polyak K., Lee M.H., Erdjument-Bromage H., Koff A., Roberts J.M., Tempst P., et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78 (1994) 59-66
7. Matsuoka S., Edwards M.C., Bai C., Parker S., Zhang P., Baldini A., et al. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9 (1995) 650-662
8. LaBaer J., Garrett M.D., Stevenson L.F., Slingerland J.M., Sandhu C., Chou H.S., et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev 11 (1997) 847-862
9. Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18 (1999) 1571-1583
10. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13 (1999) 1501-1512
11. Fero M.L., Randel E., Gurley K.E., Roberts J.M., and Kemp C.J. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396 (1998) 177-180
12. Katayose Y., Kim M., Rakkar A.N., Li Z., Cowan K.H., and Seth P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 57 (1997) 5441-5445
13. Levkau B., Koyama H., Raines E.W., Clurman B.E., Herren B., Orth K., et al. Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell 1 (1998) 553-563
14. Durand B., Gao F.B., and Raff M. Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation. EMBO J 16 (1997) 306-317
15. Onishi T., and Hruska K. Expression of p27Kip1 in osteoblast-like cells during differentiation with parathyroid hormone. Endocrinology 138 (1997) 1995-2004
16. Ophascharoensuk V., Fero M.L., Hughes J., Roberts J.M., and Shankland S.J. The cyclin-dependent kinase inhibitor p27Kip1 safeguards against inflammatory injury. Nat Med 4 (1998) 575-580
17. St Croix B., Flørenes V.A., Rak J.W., Flanagan M., Bhattacharya N., Slingerland J.M., et al. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 2 (1996) 1204-1210
18. Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 8 (2002) 1136-1144
19. Kip1 at threonine 157 and modulation of its cellular localization. Nat Med 8 (2002) 1145-1152
20. Liang J., Zubovitz J., Petrocelli T., Kotchetkov R., Connor M.K., Han K., et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8 (2002) 53-60
21. Fujita N., Sato S., Katayama K., and Tsuruo T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 277 (2002) 28706-28713
22. Kip1 and cyclin D1 through multiple signaling pathways. Cancer Res 61 (2001) 6583-6591
23. Mansouri A., Ridgway L.D., Korapati A.L., Zhang Q., Tian L., Wang Y., et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278 (2003) 19245-19256
24. Fiorentino M., Altimari A., D'Errico A., Cukor B., Barozzi C., Loda M., et al. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res 6 (2000) 3966-3972
25. kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94 (1997) 6380-6385
26. Signoretti S., Di Marcotullio L., Richardson A., Ramaswamy S., Isaac B., Rue M., et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 110 (2002) 633-641
27. Conway K.E., McConnell B.B., Bowring C.E., Donald C.D., Warren S.T., and Vertino P.M. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res 60 (2000) 6236-6242
28. Kip1 and inactivation of cdk2 kinase. Blood 96 (2000) 2746-2754
29. Esposito V., Baldi A., De Luca A., Groger A.M., Loda M., Giordano G.G., et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57 (1997) 3381-3385
30. Mori M., Mimori K., Shiraishi T., Tanaka S., Ueo H., Sugimachi K., et al. p27 expression and gastric carcinoma. Nat Med 3 (1997) 593
31. Catzavelos C., Bhattacharya N., Ung Y.C., Wilson J.A., Roncari L., Sandhu C., et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3 (1997) 227-230
32. Loda M., Cukor B., Tam S.W., Lavin P., Fiorentino M., Draetta G.F., et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3 (1997) 231-214
33. KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene 18 (1999) 1663-1676
34. Park K.H., Seol J.Y., Kim T.Y., Yoo C.G., Kim Y.W., Han S.K., et al. An adenovirus expressing mutant p27 showed more potent antitumor effects than adenovirus-p27 wild type. Cancer Res 61 (2001) 6163-6169
35. Kip1. Prostate 53 (2002) 77-87
36. Rakkar A.N., Li Z., Katayose Y., Kim M., Cowan K.H., and Seth P. Adenoviral expression of the cyclin-dependent kinase inhibitor p27Kip1: a strategy for breast cancer gene therapy. J Natl Cancer Inst 90 (1998) 1836-1838
37. Craig C., Wersto R., Kim M., Ohri E., Li Z., Katayose D., et al. A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 14 (1997) 2283-2289
38. Wang X., Gorospe M., Huang Y., and Holbrook N.J. p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene 15 (1997) 2991-2997
39. Katayose Y., Kim M., Rakkar A.N., Li Z., Cowan K.H., and Seth P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 57 (1997) 5441-5445
40. Naruse I., Hoshino H., Dobashi K., Minato K., Saito R., and Mori M. Over-expression of p27kip1 induces growth arrest and apoptosis mediated by changes of pRb expression in lung cancer cell lines. Int J Cancer 88 (2000) 377-383
41. Shin I., Rotty J., Wu F.Y., and Arteaga C.L. Phosphorylation of p27Kip1 at Thr-157 interferes with its association with importin alpha during G1 and prevents nuclear re-entry. J Biol Chem 280 (2005) 6055-6063
42. Masaki T., Shiratori Y., Rengifo W., Igarashi K., Yamagata M., Kurokohchi K., et al. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 37 (2003) 534-543
43. Singh S.P., Lipman J., Goldman H., Ellis Jr. F.H., Aizenman L., Cangi M.G., et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 58 (1998) 1730-1735
44. Pagano M., Tam S.W., Theodoras A.M., Beer-Romero P., Del Sal G., Chau V., et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269 (1995) 682-685
45. Sheaff R.J., Groudine M., Gordon M., Roberts J.M., and Clurman B.E. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 11 (1997) 1464-1478
46. Vlach J., Hennecke S., and Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 16 (1997) 5334-5344
47. Sutterlüty H., Chatelain E., Marti A., Wirbelauer C., Senften M., Müller U., et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1 (1999) 207-214
48. Carrano A.C., Eytan E., Hershko A., and Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1 (1999) 193-199
49. 1 transition mediated by a Skp2-independent ubiquitination pathway. J Biol Chem 276 (2001) 48937-48943
50. Kip1 at G1 phase. Nat Cell Biol 6 (2004) 1229-1235
51. Tomoda K., Kubota Y., and Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 398 (1999) 160-165
52. Kip1 and regulates cell cycle progression. EMBO J 21 (2002) 3390-3401
53. Ishida N., Hara T., Kamura T., Yoshida M., Nakayama K., and Nakayama K.I. Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem 277 (2002) 14355-14358
54. Liang J., Zubovitz J., Petrocelli T., Kotchetkov R., Connor M.K., Han K., et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8 (2002) 1153-1160
55. Kip1 at threonine 157 and modulation of its cellular localization. Nat Med 8 (2002) 1145-1152
56. Fujita N., Sato S., and Tsuruo T. Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. J Biol Chem 278 (2003) 49254-49260
57. Rodier G., Montagnoli A., Di Marcotullio L., Coulombe P., Draetta G.F., Pagano M., et al. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J 20 (2001) 6672-6682